Investment Summary |
|
---|---|
Date | 2015-05-01 |
Target | Toppr |
Sector | Internet Software and Services |
Investor(s) | Eight Roads |
Deal Type | Venture |
SEARCH BY
Try For Free 7-Day Free Trial
Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.
DEAL STATS | # |
---|---|
Overall | 104 of 298 |
Sector (Internet Software and Services) | 24 of 60 |
Type (Venture) | 86 of 269 |
Country (India) | 15 of 38 |
Year (2015) | 16 of 26 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-04-29 |
Blueprint Medicines
Cambridge, Massachusetts, United States Blueprint Medicines is a bio pharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Blueprint Medicines was founded in 2008 and is based in Cambridge, Massachusetts. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-05-06 |
Adaptimmune
Abingdon, United Kingdom Adaptimmune is a clinical-stage biopharmaceutical company, that focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. Adaptimmune was founded in 2008 and is based in Abingdon, England. |
Sell | - |